A Multicenter, Randomized, Open-Label, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of VSA012 Injection in Participants With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Charlene Si
- Telefonnummer: +86-021-6107 5030
- E-post: charlene.si@bisirna.com
Studiesteder
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina
- Peking Union Medical College Hospital
-
Ta kontakt med:
- Bing Han
- Telefonnummer: 010-69151188
- E-post: Hanbing-li@sina.com.cn
-
-
Changchun
-
Jilin City, Changchun, Kina
- Jilin
-
-
Fujian
-
Quanzhou, Fujian, Kina
- Quanzhou
-
-
Guangdong
-
Guangzhou, Guangdong, Kina
- Guangzhou
-
-
Guangxi
-
Nanning, Guangxi, Kina
- Nanning
-
-
Heilongjiang
-
Harbin, Heilongjiang, Kina
- Ha'erbin
-
-
Henan
-
Zhengzhou, Henan, Kina
- Zhengzhou
-
-
Hubei
-
Wuhan, Hubei, Kina
- Wuhan
-
-
Hunan
-
Changsha, Hunan, Kina
- Changsha
-
-
Jiangsu
-
Nantong, Jiangsu, Kina
- Nantong
-
-
Shanxi
-
Xi’an, Shanxi, Kina
- Xi'an
-
-
Sichuan
-
Chengdu, Sichuan, Kina
- Chengdu
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Kina
- Institute of Hematology, Chinese Academy of Medical Sciences
-
-
Zhejiang
-
Hangzhou, Zhejiang, Kina
- The First Affiliated Hospital of Zhejiang University school of medicine
-
Ta kontakt med:
- Hongyan Tong
- Telefonnummer: 0571-87236114
- E-post: hongyantong@aliyun.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
- Male and female participants ≥ 18 years of age and BMI ≥ 18.0 kg/m2 with a diagnosis of PNH confirmed by high-sensitivity flow cytometry with clone size≥10%.
- Mean hemoglobin level <100 g/L at screening.
- LDH > 1.5 x Upper Limit of Normal (ULN) at screening.
- Vaccination against Neisseria meningitidis infection is required prior to the
- start of study treatment. If not received previously, vaccination against
- Streptococcus pneumoniae and Haemophilus influenzae infections should be given.
Exclusion Criteria:
- Known or suspected hereditary or acquired complement deficiency;
- Presence or suspicion of a systemic active bacterial, viral, or fungal infection
- History of infection with capsular bacteria (e.g., meningococcus, pneumococcus, etc.)
- Patients with reticulocytes <100x10^9/L; platelets <30x10^9/L; neutrophils <0.5x10^9/L.
- Positive of HIV, HBsAg or HCVAb.
- History of recurrent invasive infections caused by encapsulated organisms,e.g. meningococcus or pneumococcus.
- Previous splenectomy.
- A history of malignancy within 5 years before screening
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Kohort1
|
VSA012 Injection
|
|
Aktiv komparator: Cohort2
|
Eculizumab injection
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
The proportion of patients with sustained hemoglobin levels ≥ 120 g/L among those without RBC transfusion (defined as no red blood cell infusion after W2 to W26).
Tidsramme: between Week 2 and Week 26
|
between Week 2 and Week 26
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Proportion of participants achieving a sustained increase from baseline in hemoglobin levels of ≥ 20 g/L assessed among those without RBC transfusion (defined as no red blood cell infusion after W2 to W26).
Tidsramme: between Week 20 and Week 26
|
between Week 20 and Week 26
|
|
The proportion of patients with hemolysis controlled (defined as LDH < 1.5 ULN) among those without RBC transfusion
Tidsramme: between Week 20 and Week 26
|
between Week 20 and Week 26
|
|
Change (Expressed as Percentages) in Hb level from baseline
Tidsramme: between Week 20 and Week 26
|
between Week 20 and Week 26
|
|
The proportion of patients without RBC transfusion
Tidsramme: between Week 2 and Week 26
|
between Week 2 and Week 26
|
|
Change in reticulocyte count from baseline
Tidsramme: between Week 20 and Week 26
|
between Week 20 and Week 26
|
|
Change in Total bilirubin count from baseline
Tidsramme: between Week 20 and Week 26
|
between Week 20 and Week 26
|
|
Change in FACIT-F score from baseline
Tidsramme: between Week 20 and Week 26
|
between Week 20 and Week 26
|
|
The Clinical BTH Rate
Tidsramme: between Day 1 and Week 26
|
between Day 1 and Week 26
|
|
The Major Adverse Vascular Events Rate
Tidsramme: between Day 1 and Week 26
|
between Day 1 and Week 26
|
|
Incidence and severity of AEs
Tidsramme: between Day 1 and Week 26
|
between Day 1 and Week 26
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Incidence and severity of AEs
Tidsramme: between Day 1 and Week 26
|
between Day 1 and Week 26
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- VSA012-3001
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .